J Korean Med Assoc.  2006 Nov;49(11):1017-1025. 10.5124/jkma.2006.49.11.1017.

Helicobacter pylori Infection

• Song JH
• Kim JJ

• KMID: 2184723
• DOI: http://doi.org/10.5124/jkma.2006.49.11.1017

Abstract

Helicobacter pylori (H. pylori) causes chronic gastritis, peptic ulcer disease, primary B-cell gastric lymphoma, and adenocarcinoma of the stomach. The overall seroprevalence of H. pylori infection in Korea was 46.6%, and the seroprevalence increased with age and was highest in patients in their 40s. Only a fraction of people infected with H. pylori develop clinical disease. Mucosal inflammation is the basic mechanism underlying the disease development in which tissue destruction may be initiated and maintained by both the bacterial toxins and immune responses by the host. H. pylori infection can be diagnosed either by invasive techniques requiring endoscopy with biopsy (histological examination, culture, and polymerase chain reaction) or noninvasive techniques (urea breath test, serology, and detection of H. pylori antigen in stool specimens). The eradication of H. pylori infection is not easy and requires combinations of antibiotics. Even with the most effective treatment regimen currently available, the eradication is not successful in about 10~20% of patients. Seven-day triple therapy (proton pump inhibitor, amoxicillin, and clarithromycin) has been the first-line therapy for H. pylori infection in Korea. In case of failure, quadruple therapy (proton pump inhibitor, a bismuth salt, metronidazole, and tetracycline) is a very effective second-line regimen. If two or more eradication treatments fail, bacterial resistance to antibiotics should be evaluated and the regimen of third-line therapy should be selected according to the antimicrobial susceptibility results.

Keyword

Helicobacter pylori; Pathogenesis; Diagnosis; Treatment

MeSH Terms

Adenocarcinoma
Amoxicillin
Anti-Bacterial Agents
B-Lymphocytes
Bacterial Toxins
Biopsy
Bismuth
Breath Tests
Diagnosis
Endoscopy
Gastritis
Helicobacter pylori*
Helicobacter*
Humans
Inflammation
Korea
Lymphoma
Metronidazole
Peptic Ulcer
Seroepidemiologic Studies
Stomach
Amoxicillin
Anti-Bacterial Agents
Bacterial Toxins
Bismuth
Metronidazole

Reference

1. Graham DY, Sung JJ. Feldman M, Friedman LS, editors. Helicobacter pylori. Sleisenger and Fordtran's Gastrointestinal and liver disease. 2006. 8th ed. Philadelphia: WB Saunders;1049–1066.

2. Kim N. Epidemiology and transmission route of Helicobacter pylori infection. Korean J Gastroenterol. 2005. 46:153–158.

3. Kim JH, Kim HY, Kim NY, Kim SW, Kim JG, Choi KW, et al. Korea H. pylori Study Group, South Korea. Seroepidemiological study of Helicobacter pylori infection in asymptomatic people in South Korea. J Gastroenterol Hepatol. 2001. 16:969–975.

4. Kim NY, Kim JG, Kim JH, Kim HY, Kim SW, Choi KW, et al. Korean H. pylori Study Group, South Korea. Risk factors of Helicobacter pylori infection in asymptomatic Korean population. Korean J Med. 2000. 59:376–388.

5. Lee YC. Pathogenesis of Helicobacter pylori infection. Korean J Gastroenterol. 2005. 46:159–165.

6. Figueiredo C, Machado JC, Yamaoka Y. Pathogenesis of helicobacter pylori infection. Helicobacter. 2005. 10:Suppl 1. 14–20.

7. Yeo M, Hahm KB. Perspective of Helicobacter pylori research:molecular pathogenesis of Helicobacter pylori virulence factors. Korean J Gastroenterol. 2005. 46:181–188.

8. Hatakeyama M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer. 2004. 4:688–694.

9. Machado JC, Pharoah P, Sousa S, Carvalho R, Oliveira C, Sobrinho-Simoes M, et al. Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology. 2001. 121:823–829.

10. Machado JC, Figueiredo C, Canedo P, Pharoah P, Carvalho R, Sobrinho-Simoes M, et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology. 2003. 125:364–371.

11. Lee SW. Diagnosis of Helicobacter pylori infection. Korean J Gastroenterol. 2005. 46:166–171.

12. Laine L, Chun D, Stein C, El-Beblawi I, Sharma V, Chandrasoma P. The influence of size or number of biopsies on rapid urease test results: a prospective evaluation. Gastrointest Endosc. 1996. 43:49–53.

13. Midolo P, Marshall BJ. Accurate diagnosis of Helicobacter pylori. Urease tests. Gastroenterol Clin North Am. 2000. 29:871–878.

14. Nishikawa K, Sugiyama T, Kato M, Ishizuka J, Kagaya H, Asaka M, et al. A prospective evaluation of new rapid urease tests before and after eradication treatment of Helicobacter pylori, in comparison with histology, culture and 13C-urea breath test. Gastrointest Endosc. 2000. 51:164–168.

15. Tu TC, Lee CL, Wu CH, Chen TK, Chan CC, Lee MS SC, et al. Comparison of invasive and noninvasive tests for detecting Helicobacter pylori infection in bleeding peptic ulcers. Gastrointest Endosc. 1999. 49:302–306.

16. Gisbert JP, Abraira V. Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a systematic review and meta-analysis. Am J Gastroenterol. 2006. 101:848–863.

17. Vaira D, Gatta L, Ricci C, Miglioli M. Review article: diagnosis of Helicobacter pylori infection. Aliment Pharmacol Ther. 2002. 16:Suppl 1. 16–23.

18. Krogfelt KA, Lehours P, Megraud F. Diagnosis of Helicobacter pylori Infection. Helicobacter. 2005. 10:Suppl 1. 5–13.

19. Paimela HM, Oksala NK, Kaariainen IP, Carlson PJ, Kostiala AA, Sipponen PI. Faecal antigen tests in the confirmation of the effect of Helicobacter eradication therapy. Ann Med. 2006. 38:352–356.

20. Korean H. pylori Study Group. Diagnosis and treatment of Helicobacter pylori infection in Korea. Korean J Gastroenterol. 1998. 32:275–289.

21. Kim JG. Treatment of Helicobacter pylori infection. Korean J Gastroenterol. 2005. 46:172–180.

22. Chung WC, Cho YS, Jeong JJ, Lee IS, Kim SW, Park DH, et al. Eradication rate of Helicobacter pylori according to the diseases and therapeutic regimens, and reinfection rate after successful eradication in a tertiary clinic. Korean J Gastroenterol. 2003. 41:1–8.

23. Cho YJ, Chun HJ, Kim ST, Koh DW, Park JH, Hyun JH, et al. Analysis of eradication rate of Helicobacter pylori according to treatment duration by using 13C-urea breath test-comparison of OAC 7 , 10 , 14 days regimen. Korean J Gastrointest Endosc. 2001. 23:207–212.

24. Kim YS, Chun HJ, Choung RS, Kim KO, Kim YS, Hyun JH, et al. Helicobacter pylori eradication rate according to the duration of PPI based triple therapy-meta-analysis of the studies in Korea. Korean J Helicobacter Res Prac. 2002. 2:50–56.

25. Kim JM. Antibiotic resistance of Helicobacter pylori isolated from Korean patients. Korean J Gastroenterol. 2006. 47:337–349.